Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

113 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-22

Study Completion Date

2020-10-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their mixtures under medial routine at adults with tree- and/or grass-medicated pollinosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Revaccination With Pollinex® Quattro

NCT02579720

Allergic Rhinitis

COMPLETED

Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture

NCT00264459

Grass Pollen Allergy

COMPLETED PHASE3

A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis

NCT04878354

Allergy

COMPLETED PHASE3

Comparison of Perennial and Preseasonal Subcutaneous Immunotherapy

NCT01555736

Seasonal Allergic Rhinitis

COMPLETED PHASE4

Untersuchung Zur Erfassung Und Kontrolle Der Lebensqualität Unter Einer Therapie Mit Pollinex Quattro Bei Heuschnupfen

NCT03014661

Rhinitis, Allergic, Seasonal

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this non-interventional study, the change in level of allergen-specific IgE before and after 3 or more years of allergen-specific immunotherapy with Pollinex Quattro in a patient population with tree and/or grass pollen induced pollinosis and/or asthma will be analyzed. In addition, the change in medication usage, asthma status for asthmatic patients after 3, 4 or 5 years of allergen specific immunotherapy will be evaluated. Furthermore, patients will be asked for their change in quality of life after therapy end.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhinitis, Allergic Respiratory Tract Infections Allergy Allergic Asthma Allergic Conjunctivitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adults

Patients with IgE-induced Rhinitis, Conjunctivitis and/or asthma due to tree- and/or grass pollen induced allergy

Pollinex Quattro with tree- and grass pollen extracts and their mixtures

Intervention Type DRUG

retrospective analysis of patient records of allergen-specific immunotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pollinex Quattro with tree- and grass pollen extracts and their mixtures

retrospective analysis of patient records of allergen-specific immunotherapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ≥ 18 years
* Diagnosis of IgE-mediated rhinitis, conjunctivitis and bronchial asthma on grass and/or tree pollen
* completed allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts or their mixtures according to SMPC effective during immunotherapy

Exclusion Criteria

* Contraindication according to Summary of Product Characteristics (SMPC) effective during immunotherapy
* no additional allergen-specific immunotherapy with another product than Pollinex Quattro

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No